This morning, we at Crystal Research published a new Executive Informational Overview (go here to find out more about what is in an EIO) on Radient Pharmaceuticals Corp. (RPC-NYSE Amex). Read a brief overview of Radient below or visit our website at www.crystalra.com to access the full 64-page report at no charge.
Radient Pharmaceuticals Corp. (“Radient” or “the Company”), together with its wholly owned subsidiary AMDL Diagnostics Inc. (ADI), is an in vitro diagnostics (IVD) company commercializing Onko-Sure® (formerly DR-70®), a non-invasive IVD test kit that detects and monitors up to 19 types of cancer. Onko-Sure® helps physicians answer important clinical questions related to early disease detection and progression in order to ultimately improve patient outcomes and survival.
The Onko-Sure® blood test measures the accumulation of specific breakdown products in serum (blood) called fibrin and fibrinogen degradation products (FDPs). Research has found that FDP levels rise dramatically as cancer progresses. Onko-Sure® is currently cleared to monitor colorectal cancer (CRC) treatment/recurrence in the U.S.; to detect and monitor lung cancer in Canada; for use as a general cancer marker in Australia, Europe, India, Taiwan, and Vietnam; and for use in CRC patients in South Korea. Radient is working to obtain additional regulatory clearances for indications in the U.S. and abroad.
Radient’s subsidiary, ADI, operates research and development and quality control laboratories and an ISO 13485:2003-certified manufacturing facility for Onko-Sure® production.
Be the first to hear about Crystal Research’s new report releases and upcoming media coverage. Follow us on Twitter at twitter.com/crystalresearch.